Glaysher, SGabriel, FGJohnson, PPolak, MKnight, LAParker, KPoole, MNarayanan, ACree, IANHS Collaborative Research Programme for Predictive Oncology2014-12-112014-12-112010-08-242010-08-24Br J Cancer, vol.103(5), pp.656 - 6621532-1827https://hdl.handle.net/10292/8222Ovarian cancer shows considerable heterogeneity in its sensitivity to chemotherapy both clinically and in vitro. This study tested the hypothesis that the molecular basis of this difference lies within the known resistance mechanisms inherent to these patients' tumours.From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.Antineoplastic combined chemotherapy protocolsBusulfanCisplatinDeoxycytidineDrug resistanceNeoplasmDrug screening assaysAntitumorFemaleHumansOvarian neoplasmsTopotecanJournal ArticleOpenAccess10.1038/sj.bjc.6605817